These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 36662784)

  • 1. A flexible age-dependent, spatially-stratified predictive model for the spread of COVID-19, accounting for multiple viral variants and vaccines.
    Schneider KA; Tsoungui Obama HCJ; Adil Mahmoud Yousif N
    PLoS One; 2023; 18(1):e0277505. PubMed ID: 36662784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of COVID-19 vaccination campaigns accounting for antibody-dependent enhancement.
    Adil Mahmoud Yousif N; Tsoungui Obama HCJ; Ngucho Mbeutchou YJ; Kwamou Ngaha SF; Kayanula L; Kamanga G; Ibrahim TB; Bwanu Iliya P; Iyanda S; Alawam Nemer L; Helle KB; Teboh-Ewungkem MI; Schneider KA
    PLoS One; 2021; 16(4):e0245417. PubMed ID: 33886573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
    Yang W; Shaman J
    medRxiv; 2021 Nov; ():. PubMed ID: 34845460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
    Gong W; Parkkila S; Wu X; Aspatwar A
    Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden of SARS-CoV-2 infection in healthcare workers during second wave in England and impact of vaccines: prospective multicentre cohort study (SIREN) and mathematical model.
    Pople D; Monk EJM; Evans S; Foulkes S; Islam J; Wellington E; Atti A; Hope R; Robotham J; Hopkins S; Brown CS; Hall VJ;
    BMJ; 2022 Jul; 378():e070379. PubMed ID: 35858689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal SARS-CoV-2 vaccine allocation using real-time attack-rate estimates in Rhode Island and Massachusetts.
    Tran TN; Wikle NB; Albert E; Inam H; Strong E; Brinda K; Leighow SM; Yang F; Hossain S; Pritchard JR; Chan P; Hanage WP; Hanks EM; Boni MF
    BMC Med; 2021 Jul; 19(1):162. PubMed ID: 34253200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
    Sonabend R; Whittles LK; Imai N; Perez-Guzman PN; Knock ES; Rawson T; Gaythorpe KAM; Djaafara BA; Hinsley W; FitzJohn RG; Lees JA; Kanapram DT; Volz EM; Ghani AC; Ferguson NM; Baguelin M; Cori A
    Lancet; 2021 Nov; 398(10313):1825-1835. PubMed ID: 34717829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 variants and the global pandemic challenged by vaccine uptake during the emergence of the Delta variant: A national survey seeking vaccine hesitancy causes.
    AlJamaan F; Temsah MH; Alhasan K; Alenezi S; Alhaboob A; Alrabiaah A; Batais M; Alshahrani F; Assiri RA; Bafaqih H; Alaraj A; Al Qadrah B; Alhaidary A; Saad K; Saddik B; Halwani R; Rabaan AA; Al-Subaie S; Barry M; Al-Tawfiq JA
    J Infect Public Health; 2022 Jul; 15(7):773-780. PubMed ID: 35728424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Projecting the Impact of SARS-CoV-2 Variants and the Vaccination Program on the Fourth Wave of the COVID-19 Pandemic in South Korea.
    Shim E
    Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34300029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of vaccination and non-pharmaceutical interventions on SARS-CoV-2 dynamics in Switzerland.
    Shattock AJ; Le Rutte EA; Dünner RP; Sen S; Kelly SL; Chitnis N; Penny MA
    Epidemics; 2022 Mar; 38():100535. PubMed ID: 34923396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines and Public Trust: Containing COVID-19 in Cuba.
    Gorry C
    MEDICC Rev; 2022 Jan; 24(1):9-13. PubMed ID: 35157633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous vaccination interventions to reduce pandemic morbidity and mortality: Modeling the US winter 2020 COVID-19 wave.
    Hupert N; Marín-Hernández D; Gao B; Águas R; Nixon DF
    Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35012976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing two-dose vaccine resource allocation to combat a pandemic in the context of limited supply: The case of COVID-19.
    Zhu J; Wang Q; Huang M
    Front Public Health; 2023; 11():1129183. PubMed ID: 37168073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 Incidence Proportion as a Function of Regional Testing Strategy, Vaccination Coverage, and Vaccine Type.
    Totolian AA; Smirnov VS; Krasnov AA; Ramsay ES; Dedkov VG; Popova AY
    Viruses; 2023 Oct; 15(11):. PubMed ID: 38005859
    [No Abstract]   [Full Text] [Related]  

  • 18. The balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants.
    Kim D; Keskinocak P; Pekgün P; Yildirim İ
    Sci Rep; 2022 May; 12(1):7493. PubMed ID: 35523832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spread of Gamma (P.1) Sub-Lineages Carrying Spike Mutations Close to the Furin Cleavage Site and Deletions in the N-Terminal Domain Drives Ongoing Transmission of SARS-CoV-2 in Amazonas, Brazil.
    Naveca FG; Nascimento V; Souza V; Corado AL; Nascimento F; Silva G; Mejía MC; Brandão MJ; Costa Á; Duarte D; Pessoa K; Jesus M; Gonçalves L; Fernandes C; Mattos T; Abdalla L; Santos JH; Martins A; Chui FM; Val FF; de Melo GC; Xavier MS; Sampaio VS; Mourão MP; Lacerda MV; Batista ÉLR; Magalhães ALÁ; Dábilla N; Pereira LCG; Vinhal F; Miyajima F; Dias FBS; Dos Santos ER; Coêlho D; Ferraz M; Lins R; Wallau GL; Delatorre E; Gräf T; Siqueira MM; Resende PC; Bello G;
    Microbiol Spectr; 2022 Feb; 10(1):e0236621. PubMed ID: 35196783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.